🔗 Share this article

While America continues making sweeping adjustments to its vaccine guidelines, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning COVID-19 vaccines in the global health crisis and has zeroed in on alleged deaths after COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Program

Public health authorities had intended to announce radical changes to the pediatric vaccination calendar in December, synchronizing the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US out of step with much of the international standard with no evidence for improved outcomes. The announcement has been delayed until the new year.

Instead of Vinay Prasad, Høeg is listed to speak at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the office this calendar year.

A New Direction at the FDA

This interim role might represent a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for discontinuing some childhood vaccine recommendations in the US so as to align more in line with Denmark's approach, a country with comprehensive healthcare and a population about the size of Wisconsin’s.

To date public appearances, she has kept her attention on vaccines – traditionally the purview of Dr. Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

The appointee has little discernible track record in medication creation, oversight or management, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have the necessary background” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a large organization. She is not an expert in drug approvals.”

Past directors of the center would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she lacks the type of experience that prior appointees who ran the center have had.”

CDER has an immense range of responsibilities at the agency, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes numerous generic medications. There’s a biologic copycat branch, over-the-counter program and other areas, and every single one must be supervised,” she explained. “The thing you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management component to the job, which manages over 5,000 employees. “It’s a massive administrative position, if you do it right,” she added.

Agency Reaction and Disputed Programs

When asked about questions about Høeg’s qualifications and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a spokesperson said that the “inquiries stem from inaccurate assumptions”.

“This background aligns with the duties of her position,” the representative explained, noting the period Høeg spent guiding the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a disputed rapid medication authorization process that apparently worried her predecessors. “By what process are these drugs being selected for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of confidentiality going on at the agency right now.”

Overall, he stated, “the FDA appears to be shifting towards laxer rules of pharmaceuticals, except for vaccines.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if concerning, past, critics said. She published a analysis using unverified crowd-sourced reports to determine the incidence of myocarditis after COVID-19 vaccination. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming government included changing rules for new vaccines and ending “optional” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has according to sources suggested excluding teenage boys from receiving Covid vaccines.

“She is an thorough true believer who begins with her preconceived notions and works backwards to retrofit the data in a extremely deceptive, fraudulent manner,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|